New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
08:21 EDTSQNM, FLDM, PKI, DDXS, WAT, PACB, AFFXMaxim recommends life science tools, diagnostics ahead of earnings
Maxim expects 2014 to be a "great year" for life science tools and diagnostics stocks and recommends buying Affymetrix (AFFX), diaDexus (DDXS), Fluidigm (FLDM), Pacific Biosciences (PACB), PerkinElmer (PKI), Sequenom (SQNM) and Waters (WAT) ahead of the Q4 results. Maxim has a preference for Pacific Biosciences, PerkinElmer and Waters. The firm raised its price target for Fluidigm to $52 from $42 and for Pacific Biosciences to $9 from $8.
News For AFFX;DDXS;FLDM;PACB;PKI;SQNM;WAT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 4, 2015
08:42 EDTFLDMFluidigm management to meet with Leerink
Subscribe for More Information
September 2, 2015
07:05 EDTSQNMSequenom announces partnership with Perinatal Quality Foundation
Subscribe for More Information
August 28, 2015
16:40 EDTSQNMSequenom files $300M mixed securities shelf
Subscribe for More Information
August 27, 2015
10:00 EDTWAT, PKI, PACB, FLDM, AFFXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
August 26, 2015
16:21 EDTWATWaters initiated with a Buy at Cantor
Subscribe for More Information
16:20 EDTPKIPerkinElmer initiated with a Buy at Cantor
Target $62.
16:16 EDTPACBPacific Biosciences initiated with a Buy at Cantor
Target $9.
16:14 EDTFLDMFluidigm initiated with a Hold at Cantor
Subscribe for More Information
16:10 EDTAFFXAffymetrix initiated with a Buy at Cantor
Subscribe for More Information
09:20 EDTFLDMFluidigm has negative read through from Becton Dickinson deal, says Leerink
Subscribe for More Information
August 25, 2015
17:32 EDTSQNMSequenom enters collaboration with UC San Diego Moores Cancer Center
Subscribe for More Information
August 24, 2015
08:29 EDTSQNMWilliam Blair to hold a field trip
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use